Unilever has ruled out increasing its £50bn offer for GlaxoSmithKline’s consumer health business, in a climbdown that comes after an intensifying investor backlash.
聯合利華(Unilever)排除了提高對葛蘭素史克(GlaxoSmithKline)消費者健康業務500億英鎊的報價的可能性。在投資者強烈反對之后,聯合利華做出了讓步。
您已閱讀5%(248字),剩余95%(5040字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。